文献速递造血干细胞移植与细胞治疗白血病

HLA配型对未处理单倍体相合造血干细胞移植结局的影响受GVHD预防方案调节

The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis.
PubMed 文献 · Blood Adv · 2017-04-21

研究纳入509例未处理单倍体相合造血干细胞移植的急性白血病患者,比较PTCy(N=313)与ATG(N=196)方案下供受体HLA错配对结局的影响。PTCy方案中HLA-DRB1抗原水平错配是≥2级aGVHD的独立危险因素(HR 2.0,95%CI 1.2-4.0,P=.02),ATG方案中未见此关联(HR 1.3,95%CI 0.4-3.4,P=.6)。HLA错配累计数与GVHD无显著关联,HLA配型状态与其他终点亦无显著关联。

要点

  • PTCy方案中HLA-DRB1抗原错配是≥2级aGVHD独立危险因素(HR 2.0,95%CI 1.2-4.0,P=.02)。
  • ATG方案中HLA-DRB1抗原错配与≥2级aGVHD无显著关联(HR 1.3,95%CI 0.4-3.4,P=.6)。
  • HLA错配累计数与GVHD无显著关联,HLA配型状态与移植相关死亡、无病生存及复发无显著关联。

核心结论

  • 基于这些数据,非共享单倍型上的HLA错配作用似乎不足以突出到支持在单倍体相合供者选择中考虑其。
  • 然而,HLA配型在单倍体相合HSCT中的作用可能受GVHD预防方案调节,需要在这一日益相关的领域进一步研究。

研究设计与样本

  • 研究评估了509例因急性白血病接受未处理单倍体相合HSCT的供受体HLA-A、-B、-C和-DRB1抗原及等位基因错配(位于错配单倍型上)对结局的影响。
  • 移植在PTCy方案(N=313)或ATG方案(N=196)下进行。

主要发现

  • HLA-DRB1位点抗原错配(而非等位基因错配)是PTCy方案中≥2级aGVHD的独立危险因素(HR 2.0,95%CI 1.2-4.0,P=.02),但在ATG方案中不是(HR 1.3,95%CI 0.4-3.4,P=.6)。
  • 在PTCy方案中(而非ATG方案),aGVHD风险与其他影响同种异体反应性的因素显著相关:外周血作为干细胞来源(HR 2.2,95%CI 1.4-3,P<.01)、减低强度预处理(HR 0.6,95%CI 0.4-0.9,P=.04)和女性供者(HR 1.8,95%CI 1-3.2,P=.05)。
  • HLA错配累计数与GVHD之间未发现显著关联。
  • HLA配型状态与包括移植相关死亡、无病生存和复发在内的其他研究终点之间未发现显著关联。

临床怎么用

  • 作者认为,基于这些数据,非共享单倍型上的HLA错配作用似乎不足以突出到支持在单倍体相合供者选择中考虑其。
  • 作者指出,HLA配型在单倍体相合HSCT中的作用可能受GVHD预防方案调节,需要进一步研究。

局限性

  • 作者指出需要在这一日益相关的领域进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with unmanipulated grafts is increasingly adopted for high-risk acute leukemia, with acute graft-versus-host disease (aGVHD) prophylaxis based on antithymocyte globulin (ATG) or posttransplant cyclophosphamide (PTCy) as main platforms. No consensus exists on selection criteria over several haploidentical donors. We evaluated the impact of donor-recipient antigenic and allelic HLA-A, -B, -C, and -DRB1 mismatches on mismatched haplotype on outcomes of 509 unmanipulated haplo-HSCTs performed for acute leukemia under a PTCy (N = 313) or ATG (N = 196) regimen. An antigenic but not allelic mismatch at the HLA-DRB1 locus was an independent risk factor for grade ≥2 aGVHD in PTCy (hazard ratio [HR], 2.0; 95% confidence interval [CI], 1.2-4.0; P = .02) but not in ATG regimens (HR, 1.3; 95% CI, 0.4-3.4; P = .6). Moreover, the hazards of aGVHD were significantly associated with other factors influencing alloreactivity, including peripheral blood as stem cell source (HR, 2.2; 95% CI, 1.4-3; P < .01), reduced-intensity conditioning (HR, 0.6; 95% CI, 0.4-0.9; P = .04), and female donors (HR, 1.8; 95% CI, 1-3.2; P = .05), in PTCy but not ATG regimens. No significant associations were found between cumulative number of HLA mismatches and GVHD, or between HLA-matching status and other study end points including transplant-related mortality, disease-free survival, and relapse. Based on these data, the role of HLA mismatching on unshared haplotype appears not to be sufficiently prominent to justify its consideration in haploidentical donor selection. However, the role of HLA matching in haploidentical HSCT might be modulated by GVHD prophylaxis, calling for further investigations in this increasingly relevant field.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lorentino F, Labopin M, Fleischhauer K, et al. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Adv. 2017. PMID: 29296709. doi:10.1182/bloodadvances.2017006429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。